What Precision Medicine Can Learn from Rare Genetic Disease Research and Translation
Authors:
- 1 September 2018
- journal article
- Published by American Medical Association (AMA) in AMA Journal of Ethics
- Vol. 20 (9) , E834-840
Abstract
The goal of this article is to examine the intersections of precision health and rare diseases. Specifically we propose 3 lessons from the last decade of applying genomics to rare diseases: (1) precision can end one odyssey and start another; (2) precise interventions can exacerbate health disparities and create other ethical dilemmas; and (3) democratization of data will transform research and translation. By studying experiences of patients with rare diseases researchers clinicians and policymakers can anticipate similar challenges in precision medicine and hopefully mitigate potential harms or injustices.Keywords
This publication has 8 references indexed in Scilit:
- Ethical Challenges Confronted When Providing Nusinersen Treatment for Spinal Muscular AtrophyJAMA Pediatrics, 2018
- Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy TherapyDrugs, 2018
- International Cooperation to Enable the Diagnosis of All Rare Genetic DiseasesThe American Journal of Human Genetics, 2017
- Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung CancerHematology/Oncology Clinics of North America, 2017
- Gene discovery for Mendelian conditions via social networking: de novo variants in KDM1A cause developmental delay and distinctive facial featuresGenetics in Medicine, 2015
- The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treatedGenetics in Medicine, 2014
- Science and the Sources of HypePublic Health Genomics, 2012
- Science communication in transition: genomics hype, public engagement, education and commercialization pressuresClinical Genetics, 2006